CLBS
Caladrius Biosciences, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 7, 4:34 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q3 EPS of -$1.09 beats by $0.46.
    • Revenue of $9.3M (+57.9% Y/Y) beats by $1.72M.
    • Press Release
    | Mon, Nov. 7, 4:34 PM | 1 Comment
  • Mon, Sep. 19, 9:50 AM
    • Adaptimmune Therapeutics (ADAP +0.4%announces that it has entered into a new five-year strategic manufacturing  agreement with PCT, a subsidiary of Caladrius Biosciences (NASDAQ:CLBS) for the supply of Adaptimmune’s SPEAR T-cell therapies. Under the contract, Adaptimmune will benefit from exclusive access to an EU and FDA compliant manufacturing unit at PCT as well as dedicated, specialist staff.
    • Adaptimmune’s relationship with PCT, a contract manufacturer of patient cell therapy products, is intended to provide Adaptimmune with maximum operational flexibility for the manufacture of its SPEAR T-cell products from development, through clinical manufacturing and ultimately, subject to marketing authorizations, into commercialization.
    • Adaptimmune’s SPEAR T-cell therapies are novel cancer immunotherapies that use enhanced affinity T-cell receptors (TCRs) to target and destroy cancer cells by strengthening a patient’s natural T-cell response. T-cells are a type of white blood cell that play a central role in a person’s immune response to disease.
    | Mon, Sep. 19, 9:50 AM | 2 Comments
  • Thu, Sep. 15, 12:56 PM
    | Thu, Sep. 15, 12:56 PM | 3 Comments
  • Thu, Sep. 15, 8:47 AM
    • Caladrius Biosciences (NASDAQ:CLBS) enters into Securities Purchase Agreements with accredited investors for the direct sale of 4,449,153 shares of common stock at $4.72. Buyers include its largest institutional investor, Sanford Health, who invested $5M in the deal.
    • The $21M total investment will be made in two tranches: $12.6M no later than September 19 and $8.4M after the enrollment of 70 patients in the company's Phase 2 Sanford Project T-Rex Study of CLBS03 in adolescents with recent onset type 1 diabetes.
    • Net proceeds will fund T-Rex, principal and interest payments on its loan from Oxford Finance, LLC, working capital and general corporate purposes.
    • Yesterday's close was $4.34.
    • Previously: Caladrius Bio teams up with Sanford Research in diabetes (Sept. 22, 2015)
    | Thu, Sep. 15, 8:47 AM
  • Fri, Aug. 26, 7:15 AM
    • Actinium Pharmaceuticals (NYSEMKT:ATNM) initiated with Buy rating and $5 (194% upside) price target by Roth Capital.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Neutral rating by Janney Montgomery Scott.
    • Cantel Medical (NYSE:CMN) initiated with Hold rating by Needham.
    • Patheon NV (Pending:PTHN) initiated with Outperform rating by William Blair.
    • Caladrius Biosciences (NASDAQ:CLBS) initiated with Buy rating and $6.50 (31% upside) price target by Chardan Capital.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) initiated with Buy rating and $5 (92% upside) price target by Rodman & Renshaw.
    • Rockwell Medical (NASDAQ:RMTI) initiated with Buy rating and $12 (72% upside) price target by BTIG Research.
    • Agios Pharmaceuticals (NASDAQ:AGIO) initiated with Neutral rating by BTIG Research.
    • TRACON Pharmaceuticals (NASDAQ:TCON) initiated with Buy rating and $15 (137% upside) price target by BTIG Research.
    • Ophthotech (NASDAQ:OPHT) initiated with Buy rating and $92 (76% upside) price target by BTIG Research.
    • Merrimack Pharmaceuticals (NASDAQ:MACK) initiated with Neutral rating by BTIG Research.
    • Acceleron Pharma (NASDAQ:XLRN) initiated with Buy rating and $46 (55% upside) price target by BTIG Research.
    | Fri, Aug. 26, 7:15 AM | 15 Comments
  • Tue, Aug. 9, 4:41 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q2 EPS of -$1.33 beats by $0.40.
    • Revenue of $8.3M (+41.4% Y/Y) beats by $0.77M.
    • Press Release
    | Tue, Aug. 9, 4:41 PM
  • Thu, May 5, 4:25 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q1 EPS of -$0.21 misses by $0.03.
    • Revenue of $7.49M (+136.3% Y/Y) misses by $0.28M.
    | Thu, May 5, 4:25 PM | 7 Comments
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Tue, Mar. 15, 4:20 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q4 EPS of -$0.59 may not be comparable to consensus of -$0.28.
    • Revenue of $7.56M (+43.2% Y/Y) misses by $0.11M.
    | Tue, Mar. 15, 4:20 PM
  • Mon, Mar. 14, 12:35 PM
    • Hitachi Chemical (OTCPK:HCHMY) establishes a 19.9% stake in Caladrius Biosciences (CLBS +16.8%) in conjunction with their global regenerative medicine collaboration. Under the terms of the partnership, Caladrius subsidiary PCT, LLC, will license its cell therapy technology and know-how to Hitachi for certain Asian territories, including Japan. Caladrius will receive an upfront payment and near-term milestones of $5.6M. Hitachi will pay service fees and royalties on contract revenue in its territories as well as all capital and operational expenses associated with ramping up the business on which PCT is entitled to royalties.
    • Hitachi and PCT are also mulling a joint venture in Europe.
    | Mon, Mar. 14, 12:35 PM | 4 Comments
  • Thu, Jan. 7, 12:41 PM
    | Thu, Jan. 7, 12:41 PM | 1 Comment
  • Wed, Jan. 6, 4:34 PM
    • Thinly traded nano cap Caladrius Biosciences (NASDAQ:CLBS), formerly NeoStem, is down 25% after hours on light volume in response to its announcement that it will terminate the Phase 3 development of lead product candidate, CLBS20, for the treatment of metastatic melanoma due to improved outcomes of combination therapies and immune checkpoint inhibitors. The company does not believe CLBS20 as monotherapy can sufficiently distance itself from alternative treatments in melanoma so it will shift its priorities to collaborating with another firm to advance development in a combination approach. The decision will result in the elimination of 40 jobs at its Irvine, CA facility. A restructuring charge of $1M will be recorded this quarter.
    • The company will focus its development efforts on its T regulatory cell therapy candidate, CLBS03. A Phase 2 clinical trial in adolescents with recent-onset type 1 diabetes should commence this quarter.
    • Management expects ~$23M in total revenues for 2015 and more than $30M this year. To accommodate the projected growth, it expects to spend $6M in capital improvements at its Allendale, NJ site.
    • Caladrius will host a conference call tomorrow morning at 8:30 am ET to discuss its plans.
    • Previously: Caladrius Bio teams up with Sanford Research in diabetes (Sept. 22, 2015)
    | Wed, Jan. 6, 4:34 PM | 16 Comments
  • Nov. 27, 2015, 9:19 AM
    | Nov. 27, 2015, 9:19 AM | 12 Comments
  • Nov. 6, 2015, 9:27 AM
    | Nov. 6, 2015, 9:27 AM | 2 Comments
  • Nov. 5, 2015, 5:49 PM
    • Caladrius Biosciences (NASDAQ:CLBS): Q3 EPS of -$0.21 beats by $0.13.
    • Revenue of $5.9M (+43.2% Y/Y) beats by $0.67M.
    | Nov. 5, 2015, 5:49 PM | 3 Comments
  • Sep. 22, 2015, 7:59 AM
    • Caladrius Biosciences (NASDAQ:CLBS), formerly NeoStem, enters into a collaboration agreement with South Dakota-based Sanford Research to develop the company's T regulatory cell therapy product candidate, CLBS03, for the treatment of adolescents with recent-onset type 1 diabetes (T1D). The partnership will focus initially on the initiation of a Phase 2 clinical trial, called The Sanford Project Trutina Study, which should start in Q1 2016.
    • Sanford, a non-profit research organization, will provide and cover the costs of two initial clinical performance sites. It will be responsible for enrolling study participants across its nine-state footprint. It will support the trial by providing funding and operational resources while Caladrius will supply CLBS03.
    • The Trutina Study will enroll 111 subjects across 12 - 15 sites in the U.S. They will be randomized to receive either 10M or 20M cells/kg. The primary endpoint is preservation of C-peptide, a measure of the preservation of beta-cell function, versus placebo. Beta cells, located in the pancreas, store and release insulin.
    • CLBS03 is a personalized medicine consisting of the patient's own T cells which have been expanded in number and functionally enhanced by a proprietary method.
    | Sep. 22, 2015, 7:59 AM | 2 Comments